Background: Intra-articular corticosteroids are a mainstay in the treatment of knee osteoarthritis, and in clinical trials,
O steoarthritis is the most common joint disorder in the United States, affecting at least twenty-seven million adults 1, 2 . Historically, osteoarthritis has been considered a mechanical disorder, but it is increasingly recognized that local inflammation, in particular, synovitis, is important in its pathophysiology [3] [4] [5] . Because synovitis is associated with both clinical symptoms and disease progression 4 , it is an important target for therapeutic intervention. The inflamed synovium is a likely site of action of intra-articular corticosteroids 6, 7 , which have, over the last six decades, become a mainstay of treatment for osteoarthritis pain 8 . The U.S. Food and Drug Administration (FDA) labeling for these therapies and guidelines of professional societies recommend corticosteroids for short-term treatment of pain [9] [10] [11] [12] [13] . The growth in the use of these therapies has been continuous, and it was estimated that, in 2012, more than three million patients with knee osteoarthritis had received intra-articular corticosteroids in the United States 14 .
In clinical trials, intra-articular corticosteroids demonstrate a large initial analgesic effect that wanes over one to four weeks [15] [16] [17] with the rapid efflux of drug from the joint 18 . FX006 is an extended-release formulation of triamcinolone acetonide in poly(lactic-co-glycolic acid) (PLGA) microspheres that is designed to maintain therapeutic concentrations of triamcinolone acetonide in the joint over a period of months. In a previous pharmacokinetic study of FX006 in patients with knee osteoarthritis, both prolonged residency of triamcinolone acetonide in the joint and reduced plasma concentrations relative to an equivalent dose of immediate-release triamcinolone acetonide were demonstrated 19 . The primary objective of the present study was to determine if FX006 provides pain relief superior to that provided by immediaterelease triamcinolone acetonide. This is the first clinical report assessing efficacy following intra-articular injection of a corticosteroid formulated for extended release.
Materials and Methods
Trial Design I n this Phase-2, multicenter, randomized, double-blind, active-comparator, parallel-group study, which was approved by appropriate institutional review boards, written informed consent was obtained and eligible patients with knee osteoarthritis were randomized (1:1:1:1) to a single intra-articular injection of FX006 (containing 10, 40, or 60 mg of triamcinolone acetonide) or 40 mg of immediate-release triamcinolone acetonide (Kenalog-40/Kenacort-40). An unblinded statistician generated subject and material randomization schedules, which were transferred to an interactive web response system. A blinded site team member accessed the interactive web response system to randomize each subject. The system specified the study drug vial type to be dispensed using only a vial number.
Over twelve weeks, data on the mean daily pain on the 11-point Numeric Rating Scale, in which 0 points indicate no pain and 10 points indicate the worst imaginable pain, were collected with an interactive voice-response system patient diary. 20 and
Patient Global Impression of Change. A blinded assessor completed the Clinician Global Impression of Change. At all outpatient visits, blood samples were collected for laboratory analyses (hematology, chemistry, and triamcinolone acetonide concentration), electrocardiograms and vital signs were recorded, and adverse events or changes in concomitant medications were documented. Plasma samples were assayed for triamcinolone acetonide concentrations using a validated high-performance liquid chromatography with tandem mass spectrometry (LC/MS/MS) bioanalytical method (see Appendix). This study was registered at ClinicalTrials.gov (NCT01487161).
Participants
A total of 229 patients from twenty-two study centers in Canada (twelve centers), Australia (eight centers), and the United States (two centers) were randomized; 228 patients were treated. Eligible patients were at least forty years old, with a body mass index of £40 kg/m 2 and a diagnosis of unilateral or bilateral osteoarthritis of the knee for at least six months prior to screening consistent with American College of Rheumatology Criteria for Classification of Idiopathic OA of the Knee 21 . A mean of ‡5 points and £9 points on the twenty-four-hour mean pain score (on the 0 to 10-point Numeric Rating Scale) for at least five of the seven days prior to day 1 and a Kellgren-Lawrence grade of 2 or 3 were also required 22 . Patients agreed to abstain from using restricted medications and non-pharmacologic therapies during the study. Patients were allowed to take study-issued acetaminophen or paracetamol (up to 3 g/day) as rescue medication.
Patients were excluded if they had received an intra-articular corticosteroid in any joint within three months of screening; oral, inhaled, or intranasal corticosteroids within one month; intra-articular hyaluronic acid in the index knee within six months; or prior arthroscopic or open surgery of the index knee within twelve months. Advertisement was employed in recruitment of approximately 15% of the enrolled patients.
Interventions
Patients received a single intra-articular injection of FX006 (10, 40, or 60-mg triamcinolone acetonide) or immediate-release triamcinolone acetonide (40 mg) on day 1. Physical barriers prevented patients from viewing the injection syringe and the unblinded injectors did not participate in any other clinical evaluation. The injector chose the position of the knee and the approach for the injection. Prior to injection, the index knee was cleansed and was sprayed with ethyl chloride. Following aspiration of synovial fluid, 3 mL of the reconstituted FX006 or 1 mL of immediate-release triamcinolone acetonide was injected into the synovial space using a 22-gauge, 1.5 or 2-inch needle (see Appendix). No anesthetic was injected as part of treatment. In patients with bilateral osteoarthritis, the knee with greater baseline pain was injected. Patients were advised to rest and to avoid weight-bearing for twenty-four hours after injection.
Outcomes
The primary efficacy outcome measure was the weekly mean of the mean daily pain intensity scores. Mean daily pain was reported by each patient using a validated daily pain diary consisting of a single item (adapted from the Brief Pain Inventory 23 ) that assessed mean pain over the previous twenty-four hours using the 0 to 10-point Numeric Rating Scale. 
Sample Size
In this Phase-2 dose-ranging study, priority was given to maximizing statistical power via use of one-sided Type-1 error (alpha level), and a sample size of 224 patients (fifty-six patients per treatment group to yield fifty-one patients for analysis) was specified to provide 80% power (alpha = 0.05, one-sided) if the true underlying FX006 mean difference from control 25 was 1 unit on the 0 to 10-point Numeric Rating Scale with an assumed standard deviation of ;2.
Statistical Methods
The primary efficacy end point was the change from baseline to each of eight, ten, and twelve weeks in the weekly mean of the mean daily pain intensity scores for the full analysis set (all patients who received a study treatment and had a baseline and at least one post-dose pain evaluation). The primary efficacy end point was analyzed with a longitudinal mixed-effects model with fixed effects for the treatment group, study week, treatment-by-week interaction, and baseline covariate. The subject was the random effect. For calculating the weekly means of the mean daily pain intensity scores, patients needed to have recorded at least four of the seven daily pain scores in a given week. Treatment differences from control were estimated via least square means. For the primary end point, the multiplicity of dose comparisons with the active comparator was addressed via a step-down procedure beginning with the 60-mg FX006 dose at each time point. The multiplicity of time points within each dose comparison with the immediate-release triamcinolone acetonide arm was addressed by a sensitivity analysis via a Hochberg adjustment, but not as part of the primary analysis, as this assumes independence of the tests across time. Secondary end points were assessed similarly. At each weekly assessment, the proportions of FX006 responders (>20%, >30%, and >50% improvement from baseline in mean daily pain intensity scores) were compared with those responding in the immediate-release triamcinolone acetonide arm with use of logistic regression. For the WOMAC subscales, the scores at each outpatient visit were calculated as the mean of the responses to all questions in the subscale. The Patient Global Impression of Change and the Clinician Global Impression of Change were assessed relative to baseline at each post-baseline visit. The OMERACT-OARSI responder status was calculated as a composite of the mean daily pain intensity scores, the WOMAC C function subscale, and the Patient Global Impression of Change 24 .
Source of Funding
This study was sponsored by Flexion Therapeutics, for which some authors of this study (N.B., J.L., C.W., A.K., R.B., and M.C.) are employees and other authors of this study (J.B., C.B., and D.H.) are paid consultants. Funds were used to supply study drug and materials and to support study design, clinical trial operations, and data analysis. Three authors of this study (N.B., A.K., and M.C.) have also been issued a patent through Flexion Therapeutics for corticosteroid for the treatment of joint pain, which is the FX006 used in this study.
Results

Participant Flow and Baseline Characteristics
P atient disposition is reported in Figure 1 , according to the Consolidated Standards of Reporting Trials (CONSORT) guidelines 26, 27 . A total of 390 patients were screened, 229 patients were randomized, and 228 patients were treated in this study: fifty-eight patients in the 10-mg FX006 group, fifty-nine patients CONSORT flowchart of patient disposition. TCA IR = immediate-release triamcinolone, FAS = full analysis set, AE = adverse event, and WC = withdraw consent.
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T 3, 2015 in the 40-mg FX006 group, sixty patients in the 60-mg FX006 group, and fifty-one patients in the 40-mg immediate-release triamcinolone acetonide group. Of the 228 patients, 221 (96.9%) completed the study, and seven (3.1%) prematurely discontinued. Patients were enrolled from June 2012 through January 2013, with follow-up completed in April 2013. Treatment arms were well balanced at baseline (Table I ). The weekly mean of the mean daily pain intensity scores at baseline ranged from 6.4 to 6.6 points across the four treatment groups.
Efficacy
In this study, the primary analysis was conducted on the full analysis set (Fig. 1) . The study's hierarchical testing procedure to address the multiplicity of doses initially compared the 60-mg FX006 group with the immediate-release triamcinolone acetonide group. The between-group differences in the primary efficacy outcome measure were not significant at this dose at eight weeks (p = 0.12), ten weeks (p = 0.20), and twelve weeks (p = 0.55) ( Table II) . The hierarchical testing procedure did not allow assessment of the primary end point to proceed to the 40-mg dose of FX006 in the prespecified analysis. Following the study, the technical basis for a failure of release of triamcinolone acetonide from the 60-mg dose was established (see Appendix), and the statistical testing for the 40 mg and 10-mg FX006 groups was reported as exploratory analyses (Table II) .
The 40-mg dose of FX006 produced pain relief that was superior to immediate-release triamcinolone acetonide at two through twelve weeks and was significantly superior at five to ten weeks (p < 0.05 at each time point), with mean pain reduction relative to immediate-release triamcinolone acetonide of 20.9 through that period ( Fig. 2 and Table II ); FX006 at 40 mg also demonstrated significant improvement (p < 0.05) over immediaterelease triamcinolone acetonide at eight weeks in key secondary outcomes that assessed pain, stiffness, function, Patient Global Impression of Change, Clinician Global Impression of Change, and responder status (Table III) 28 . At twelve weeks, the outcomes continued to favor the 40-mg dose of FX006, although significance was not maintained (p ‡ 0.05). Rescue medication consumption (the mean number of daily 500-mg acetaminophen tablets for each weekly interval) was consistently lower from baseline to eleven weeks in patients who received FX006 than in patients who received immediate-release triamcinolone acetonide (data not shown).
The 10-mg dose of FX006 produced effects on the primary efficacy outcome measure that were numerically improved relative to immediate-release triamcinolone acetonide at two to twelve weeks but failed to reach significance (p ‡ 0.05) at eight, ten, or twelve weeks. This dose also showed significant improvement (p < 0.05) compared with immediate-release triamcinolone acetonide in many of the secondary outcome measures at eight weeks (Table III) . 
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FX006 at 60 mg produced an effect similar to that of the 40-mg dose through six weeks (Fig. 2) . During the second six weeks of the follow-up period, the effect of the 60-mg dose diminished in magnitude, reaching a level similar to that of immediate-release triamcinolone acetonide at eleven through twelve weeks.
An inspection of mean daily pain intensity scores in Figure  2 reveals a consistent advantage for 40-mg FX006 compared with immediate-release triamcinolone acetonide throughout the twelve-week study period. Therefore, an analysis was conducted post hoc to assess the mean change from baseline over the entire ‡The values are given as the mean in points, with the 90% CI in parentheses. §The patient percentages were determined on the basis of the number of patients for whom data were available at eight weeks: fifty-seven patients in the 10-mg FX006 group, fifty-nine patients in the 60-mg FX006 group, and forty-six patients in the 40-mg TCA IR group. #The values are given as the odds ratio, with the 90% CI in parentheses. **Patients who had three or more missing scores at eight weeks were excluded from the analysis; therefore, fifty-five patients in each of the 10-mg and 40-mg FX006 groups, fifty-six patients in the 60-mg FX006 group, and forty-three patients in the 40-mg TCA IR group were included in the analysis. 
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T 3, 2015 twelve weeks. In this analysis, mean pain relief over one through twelve weeks was 62% lower than baseline (24.0 mean daily pain units) and was significantly superior to immediate-release triamcinolone acetonide (p = 0.038).
Safety
All treatments were well tolerated. Three patients were hospitalized for adverse events that were not attributed to the study treatment (coronary artery stenosis and cerebrovascular accident in the 40-mg FX006 group and subcutaneous abscess in the 60-mg FX006 group). The number of patients experiencing at least one treatment emergent adverse event was similar across the four treatment groups (Table IV) . One patient in the 10-mg FX006 arm prematurely discontinued the study because of a treatment emergent adverse event that was considered neither drug-related nor serious (worsening of right [index] knee pain). Treatment emergent adverse events categorized by system organ class that occurred in >5% of patients were also similar across treatment groups (Table V) . Although arthralgia occurred more frequently in the 40-mg FX006 group than in the other groups, the percentage of arthralgia events considered related to the study drug was consistent across treatment arms: 5.2% in the 10-mg FX006 group, 5.1% in the 40-mg FX006 group, 3.3% in the 60-mg FX006 group, and 3.9% in the immediate-release triamcinolone acetonide group. At each clinic visit, index knee assessments were conducted in a blinded fashion for signs of local inflammation, including tenderness, swelling, redness or heat, effusion, and Baker cyst. The percentage of patients shifting from signs of local inflammation at baseline to no signs of inflammation at one, two, four, eight, and twelve weeks for each of the treatment arms is shown in Table VI .
Pharmacokinetics
The mean plasma concentration-time profiles following the administration of FX006 or immediate-release triamcinolone acetonide are shown in Figure 3 . FX006 produced substantially lower peak concentrations of triamcinolone acetonide relative to immediate-release triamcinolone acetonide (13, 196 pg/mL for immediate-release triamcinolone acetonide and 707 pg/mL for FX006) at a matched dose (40 mg). *The values are given as the percentage of patients who had inflammation at baseline but had no evidence of inflammation at follow-up, with the number of patients with no inflammation at follow-up and the number of patients in each group with available data in parentheses. †TCA IR = immediate-release triamcinolone acetonide.
884
T
Discussion
T he primary objective of this study was to determine if FX006 could provide superior pain relief to immediaterelease triamcinolone acetonide in patients with knee osteoarthritis. In a previous clinical study, the 40-mg dose of FX006 demonstrated maintenance of synovial concentrations of triamcinolone acetonide consistent with pharmacologic activity for a period of at least six weeks, when levels of triamcinolone acetonide produced by an equivalent dose of immediate-release triamcinolone acetonide were below the limits of quantitation 19 . Not only did FX006 prolong the maximal effect of immediaterelease triamcinolone acetonide (which in the present study occurred at four weeks), but also, between two and eleven weeks, the analgesic effect of 40-mg FX006 exceeded the maximal effect of immediate-release triamcinolone acetonide at four weeks and was significantly superior to immediate-release triamcinolone acetonide from five weeks to ten weeks (p < 0.05 at each time point), with a mean pain reduction relative to immediate-release triamcinolone acetonide of 20.9 on the 11-point Numeric Rating Scale. Hence, the extended residency of triamcinolone acetonide in the joint with the 40-mg dose of FX006 not only prolonged but also amplified the analgesic effect. This constitutes a meaningful clinical improvement relative to immediate-release triamcinolone acetonide as evidenced by significant improvement in both the OMERACT-OARSI and the >20%, >30%, and >50% improvement responder analyses at eight weeks. Analyses of other secondary measures, including WOMAC pain, stiffness, and function subscales, Patient Global Impression of Change, and Clinician Global Impression of Change, demonstrated significant superiority to immediate-release triamcinolone acetonide.
Subsequent investigations suggest that the loss of signal associated with FX006 at 60 mg is attributable to the differential aggregation of microspheres at this concentration (see Appendix) that resulted in the premature release of triamcinolone acetonide during the first six weeks post-injection.
A likely site of action of intra-articular corticosteroids in the osteoarthritic joint is the inflamed synovium 7, 8, 29 . Synovitis has been demonstrated with both histology and imaging technologies 30 and is recognized as an important element in the pathophysiology of the disease [3] [4] [5] 30 . A number of longitudinal magnetic resonance imaging studies have directly correlated an increase in synovitis with worsening pain [31] [32] [33] . Given the known anti-inflammatory properties of corticosteroids, it is reasonable to infer that the analgesia observed following intra-articular injection is a result of the suppression of synovitis. The anti-inflammatory effects of corticosteroids are the product of repression of key inflammatory transcription factors and regulation of post-transcriptional mechanisms 29, 34 . The long-term activation of these signaling pathways (through maintenance of therapeutic intracellular triamcinolone acetonide concentrations) may be required to achieve the amplified therapeutic effect observed 
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T 3, 2015 with FX006. Consistent with long-term suppression of local inflammation by FX006 are data from index knee examinations assessing clinical signs indicative of local inflammation. At baseline, 86.8% of patients had signs of local inflammation. At every postbaseline visit, the 40-mg FX006 dose (associated with optimal analgesic effect) substantially increased the percentage of patients shifting to no evidence of inflammation relative to immediaterelease triamcinolone acetonide (Table VI) . Following injection of immediate-release triamcinolone acetonide, the plasma concentration of triamcinolone acetonide rises precipitously as the drug is rapidly absorbed into the systemic circulation. Consistent with the prolonged, relatively slow release of triamcinolone acetonide from FX006, these early peak levels of triamcinolone acetonide are not observed at any dose of FX006. This approximately eighteenfold reduction in the early peak plasma level may confer safety advantages in patients with compromised glycemic control [35] [36] [37] . There were several limitations in this study. It is noted that placebo effects are typically large in trials of intra-articular therapies 38 , and the use of an active control may have further inflated the reported therapeutic effect 39, 40 . However, this inflation of patient expectation was applicable to both arms and did not confound differentiation of the 40-mg FX006 dose from immediate-release triamcinolone acetonide.
The persistence of the analgesic effect, relative to baseline, of immediate-release triamcinolone acetonide through twelve weeks is inconsistent with a number of published reports in which the effect of intra-articular corticosteroid suspensions against placebo diminishes rapidly after one to four weeks 6, 41, 42 . Again, despite this relative increase in the signal produced by immediate-release triamcinolone acetonide, the 40-mg FX006 dose demonstrated a superior analgesic effect.
In conclusion, in this dose-ranging study of safety and efficacy in patients with knee osteoarthritis, the 40-mg dose of FX006 provided a clinically meaningful improvement in analgesia relative to immediate-release triamcinolone acetonide while substantially reducing systemic exposure. The sustained local residence of triamcinolone acetonide provided by FX006 may be of utility in the treatment of other musculoskeletal disorders and dermatologic conditions. I n a companion pharmacokinetic study, measurement of synovial triamcinolone acetonide concentrations at six weeks in patients revealed markedly lower levels at the 60-mg dose (with a geometric mean of 17,546 pg/mL) than the 40-mg dose (78,757 pg/mL) 19 . The loss of efficacy of the 60-mg FX006 dose may be associated with premature release of triamcinolone acetonide from the PLGA matrix at one through six weeks. Following reconstitution, light micrographs demonstrated large aggregates of microspheres at the 60-mg dose, which were not evident at the 10 or 40-mg doses. This likely reflects the relatively greater concentration of microspheres in the 60-mg dose (all doses were administered in a fixed volume of 3 mL) and is probably attributable to an insufficient quantity of surfactant (polysorbate-80) in the diluent used in reconstitution. Increased aggregation creates an acidic microenvironment as PLGA biodegrades to lactic acid and glycolic acid, which causes increased solubility of triamcinolone acetonide and autocatalysis of PLGA, both of which promote drug release 43, 44 . Depletion of triamcinolone acetonide attributable to premature release of triamcinolone acetonide from the 60-mg dose at one to six weeks post-injection likely results in reduced synovial concentrations of triamcinolone acetonide in subsequent weeks and the deterioration of the therapeutic effect observed at seven through twelve weeks.
Volume of Injection
In making a direct comparison with the standard of care, injection volume was not controlled. To disperse FX006 microspheres, 3 mL of diluent is required; immediate-release triamcinolone acetonide is administered as a 1-mL injection. However, the onset of the analgesic effect for 40-mg FX006 and 40-mg immediaterelease triamcinolone acetonide was similar (as shown by the percentage of patients achieving at least a 30% improvement relative to baseline in the days following injection [data not shown]), and it is unlikely, given the relatively rapid turnover in synovial fluid 45, 46 , that an effect of injection volume would be manifest at the eight-week primary end point.
Bioanalytical Methods Validation
Human plasma samples were assayed for triamcinolone acetonide concentrations with use of a validated high-performance liquid chromatographic method with tandem mass spectrometry detection. The method used an internal standard (triamcinolone-6-d1 acetonide-d6), and both triamcinolone acetonide and the internal standard were extracted and were separated with use of an isocratic chromatographic separation using a C18 column solid phase and a water or methanol mobile phase. Detection was by tandem mass spectrometry. The validated range was from 50.06 to 5006.00 pg/mL, and the range for calibration standards for sample assay was 50.00 to 5000.00 pg/mL. The range of between-run accuracy and precision biases was 21.38% to 8.09%. The range of within-run accuracy and precision biases was 21.60% to 6.01%. n NOTE: The authors acknowledge Rob Blanks for his work in the development and manufacture of the FX006 drug product. 
